(Q51792057)

12 April 2018

title

Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer. (English)

1 reference

12 April 2018

1 reference

1 reference

22

John Nemunaitis

1 reference

12 April 2018

author name string

Jonathan Oh

1

1 reference

12 April 2018

Minal Barve

2

1 reference

12 April 2018

Carolyn M Matthews

3

1 reference

12 April 2018

E Colin Koon

4

1 reference

12 April 2018

Thomas P Heffernan

5

1 reference

12 April 2018

Bruce Fine

6

1 reference

12 April 2018

Elizabeth Grosen

7

1 reference

12 April 2018

Melanie K Bergman

8

1 reference

12 April 2018

Evelyn L Fleming

9

1 reference

12 April 2018

Leslie R DeMars

10

1 reference

12 April 2018

Loyd West

11

1 reference

12 April 2018

Daniel L Spitz

12

1 reference

12 April 2018

Howard Goodman

13

1 reference

12 April 2018

Kenneth C Hancock

14

1 reference

12 April 2018

Gladice Wallraven

15

1 reference

12 April 2018

Padmasini Kumar

16

1 reference

12 April 2018

Ernest Bognar

17

1 reference

12 April 2018

Luisa Manning

18

1 reference

12 April 2018

Beena O Pappen

19

1 reference

12 April 2018

Ned Adams

20

1 reference

12 April 2018

Neil Senzer

21

1 reference

12 April 2018

language of work or name

English

0 references

publication date

24 September 2016

1 reference

12 April 2018

published in

Gynecologic Oncology

1 reference

12 April 2018

volume

143

1 reference

12 April 2018

issue

3

1 reference

12 April 2018

page(s)

504-510

1 reference

12 April 2018

Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancer

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.09.018

Consolidation and maintenance treatments for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy: a review of the literature.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.09.018

Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group tria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.09.018

First-line treatment regimens and the role of consolidation therapy in advanced ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.09.018

Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO--the MIMOSA study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.09.018

Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a Southwest Oncology Group and Gynecologic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.09.018

Incorporation of bevacizumab in the primary treatment of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.09.018

A phase 3 trial of bevacizumab in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.09.018

Maintenance chemotherapy for ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.09.018

Consolidation paclitaxel is more cost-effective than bevacizumab following upfront treatment of advanced epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.09.018

OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.09.018

Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.09.018

Emerging role for bevacizumab in combination with chemotherapy for patients with platinum-resistant ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.09.018

Immunotherapy for ovarian cancer: what's next?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.09.018

Altered expression of transforming growth factor-beta ligands and receptors in primary and recurrent ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.09.018

TGF-β blockade depletes T regulatory cells from metastatic pancreatic tumors in a vaccine dependent manner

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.09.018

Accumulation of memory precursor CD8 T cells in regressing tumors following combination therapy with vaccine and anti-PD-1 antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.09.018

Three-year Follow up of GMCSF/bi-shRNA(furin) DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.09.018

Pretreatment CA-125 and risk of relapse in advanced ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.09.018

7 January 2021

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.09.018

Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.09.018

Human ovarian carcinoma cells generate CD4(+)CD25(+) regulatory T cells from peripheral CD4(+)CD25(-) T cells through secreting TGF-beta

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.09.018

Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.09.018

Contrasting effects of TGF-beta 1 and TNF-alpha on the development of dendritic cells from progenitors in mouse bone marrow

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.09.018

Inflammation directs memory precursor and short-lived effector CD8(+) T cell fates via the graded expression of T-bet transcription factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.09.018

Recovery of CD8+ T-cell function during systemic chemotherapy in advanced ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.09.018

Molecular pathways: the immunogenic effects of platinum-based chemotherapeutics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.09.018

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.09.018

CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.09.018

Immunobiology of dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.09.018

Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.09.018

Human monoclonal antibody with dual GM2/GD2 specificity derived from an immunized melanoma patient

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.09.018

10.1016/J.YGYNO.2016.09.018

7 January 2021

Identifiers

DOI

1 reference

12 April 2018

1 reference

12 April 2018